Skip to main content

Table 1 Comparison of patient characteristics

From: Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer

Patient characteristics

All patients (n = 304)

Del-19 (n = 36)

L858R (n = 42)

p-value

(Del-19/L858R)

Wild type (n = 226)

No. of patients

%

No. of patients

%

No. of patients

%

Age (years)

 Median (range)

64.0 (37–78)

62.5 (41–77)

66.0 (38–78)

 

64.0 (37–78)

  < 65

160

20

55.6

17

40.5

0.18

123

54.4

  ≥ 65

144

16

44.4

25

59.5

 

103

45.6

Gender

 Male

216

19

52.8

15

35.7

0.13

182

80.5

 Female

88

17

47.2

27

64.3

 

44

19.5

PS (ECOG)

 0–1

273

35

97.2

40

95.2

0.65

198

87.6

 2

31

1

2.8

2

4.8

 

28

12.4

Smoking history

 Never

85

20

55.6

30

71.4

0.15

35

15.5

 Ever

219

16

44.4

12

28.6

 

191

84.5

Clinical stage

 IIIB, IV

277

30

83.3

35

83.3

1.00

212

93.8

 Recurrence

27

6

16.7

7

16.7

 

14

6.2

Histology

 Adenocarcinoma

276

34

94.4

42

100

0.30

200

88.5

 Large cell carcinoma

4

1

2.8

0

0

 

3

1.3

 NSCLC-NOS

24

1

2.8

0

0

 

23

10.2

Induction therapy cycles

 Mean (range)

3.7(1–6)

3.7 (1–6)

4.0 (1–6)

0.23

3.6 (1–6)

Maintenance therapy cycles

 Mean (range)

3.3(0–30)

4.1 (0–30)

6.0 (0–22)

0.17

2.7 (0–30)

  1. Del-19 19 deletion; L858R Leu858Arg; PS performance status
  2. ECOG Eastern Cooperative Oncology Group
  3. NSCLC-NOS non small cell lung cancer-not otherwise specified